Search

Your search keyword '"HemispheRx BioPharma Inc. -- Product development"' showing total 13 results

Search Constraints

Start Over You searched for: Descriptor "HemispheRx BioPharma Inc. -- Product development" Remove constraint Descriptor: "HemispheRx BioPharma Inc. -- Product development" Topic banking, finance and accounting industries Remove constraint Topic: banking, finance and accounting industries
13 results on '"HemispheRx BioPharma Inc. -- Product development"'

Search Results

1. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx' Ampligen and Pembrolizumab

2. Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

3. Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen(R) Phase III Trial in Patients with CFS/ME

4. Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript

5. Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

6. Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

7. FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses

8. Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment

9. FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine

10. Hemispherx Biopharma Prepares Application to Initiate Phase II Clinical Trials in China With Ampligen(R)

11. New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development

12. Hemispherx Biopharma's Ampligen NDA for Chronic Fatigue Syndrome Accepted for Review by the FDA; Marks the First Drug Candidate for Approval to Treat CFS, and the First Compound in the TLR Class

13. Hemispherx Biopharma, Inc. Completes Enrollment in Phase II Study of Ampligen as Seasonal Flu Vaccine Enhancer; Six-Month Study Will Also Assess Potential Cross-Protection Against H5N1 Avian Influenza

Catalog

Books, media, physical & digital resources